Amifostine
- Generic Name
- Amifostine
- Brand Names
- Ethyol
- Drug Type
- Small Molecule
- Chemical Formula
- C5H15N2O3PS
- CAS Number
- 20537-88-6
- Unique Ingredient Identifier
- ILA426L95O
- Background
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
- Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
- Associated Conditions
- Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
- Associated Therapies
- -
Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
Phase 1
- Conditions
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00006127
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath